| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 链球菌C5a肽酶疫苗 | CN200510052927.0 | 1999-12-03 | CN1679929B | 2012-09-26 | 保罗·帕特里克·克利里; 德博拉·K·斯塔夫斯林 |
| 本发明提供了一种用于抗β-溶血链球菌集群或感染的新型疫苗。这种疫苗包含一种具有免疫原量的链球菌C5a肽酶的突变体(SCP)，同时也提供了一种通过使用此种疫苗保护易感的哺乳动物抗β-溶血链球菌集群或感染的方法，并对无酶活性的SCP和编码SCP蛋白多聚核糖核基酸也进行了披露。 | ||||||
| 2 | 链球菌C5a肽酶疫苗 | CN99814192.5 | 1999-12-03 | CN100389198C | 2008-05-21 | 保罗·帕特里克·克利里; 德博拉·K·斯塔夫斯林 |
| 本发明提供了一种用于抗β-溶血链球菌集群或感染的新型疫苗。这种疫苗包含一种具有免疫原量的链球菌C5a肽酶的突变体(SCP)，同时也提供了一种通过使用此种疫苗保护易感的哺乳动物抗β-溶血链球菌集群或感染的方法，并对无酶活性的SCP和编码SCP蛋白多聚核糖核基酸也进行了披露。 | ||||||
| 3 | 金精三羧酸合成的复合物低分子量组分对补体的膜攻击复合物和C3转化酶的选择性抑制作用 | CN201280075715.2 | 2012-07-13 | CN104661660A | 2015-05-27 | P·麦克格尔; M·李; 郭建平; C·施瓦伯 |
| 采用分子量小于1千道尔顿的金精三羧酸复合物成分，选择性抑制哺乳动物物种优选人中的补体膜攻击复合物。优选抑制剂是金精三羧酸，金精四羧酸，和金精六羧酸。通过选择性抑制补体膜攻击复合物而治疗的优选的病症是与年龄相关的黄斑变性，阿尔茨海默病，动脉粥样硬化，类风湿关节炎，阵发性夜间血红蛋白血症，疟疾感染，与多发性硬化。 | ||||||
| 4 | 链球菌C5a肽酶疫苗 | CN200510052927.0 | 1999-12-03 | CN1679929A | 2005-10-12 | 保罗·帕特里克·克利里; 德博拉·K·斯塔夫斯林 |
| 本发明提供了一种用于抗β－溶血链球菌集群或感染的新型疫苗。这种疫苗包含一种具有免疫原量的链球菌C5a肽酶的突变体(SCP)，同时也提供了一种通过使用此种疫苗保护易感的哺乳动物抗β－溶血链球菌集群或感染的方法，并对无酶活性的SCP和编码SCP蛋白多聚核糖核基酸也进行了披露。 | ||||||
| 5 | 链球菌C5a肽酶疫苗 | CN99814192.5 | 1999-12-03 | CN1329669A | 2002-01-02 | 保罗·帕特里克·克利里; 德博拉·K·斯塔夫斯林 |
| 本发明提供了一种用于抗β－溶血链球菌集群或感染的新型疫苗。这种疫苗包含一种具有免疫原量的链球菌C5a肽酶的突变体(SCP),同时也提供了一种通过使用此种疫苗保护易感的哺乳动物抗β－溶血链球菌集群或感染的方法,并对无酶活性的SCP和编码SCP蛋白多聚核糖核基酸也进行了披露。 | ||||||
| 6 | ポリペプチドおよびその使用 | JP2016571311 | 2015-06-05 | JP2017524345A | 2017-08-31 | マイルズ・ナン; スーザン・メアリー・リー; マテイス・ミクラス・ジョア |
| 本発明は、ポリペプチドに関し、特に、補体系の活性または活性化を阻害することができるポリペプチドに関する。該ポリペプチドをコードする核酸および該ポリペプチドの使用にも関する。補体系は、生物から病原菌を排除する抗体および食細胞の能力を補助する、または“補う”。それは、自然免疫系の一部を構成する。補体活性化の下方制御は、動物モデル試験および生体外(ex vivo)試験において、いくつかの疾患の適応症の処置に有効であることが実証されている。本発明は、1つまたは複数の補体経路の不適切な活性化に関連する疾患または障害の処置のために使用できる新規なポリペプチドを提供する。 | ||||||
| 7 | Compositions and methods for the treatment of hepatic diseases and disorders | US15626055 | 2017-06-16 | US10149869B2 | 2018-12-11 | Elizabeth McKenna |
| The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes. | ||||||
| 8 | Control of Cellular Redox Levels | US15703607 | 2017-09-13 | US20180064767A1 | 2018-03-08 | Elizabeth McKenna |
| Disclosed herein are compositions and methods for regulating redox status and/or reducing oxidative stress in a subject, the methods and compositions comprising TLR agonists comprising bacterial lysates and/or lysate fractions. Also disclosed are compositions and methods comprising bacterial lysates and/or lysate fractions formulated or administered in combination with one or more other therapeutic or pharmaceutical agents. | ||||||
| 9 | Compositions and Methods for the Treatment of Hepatic Diseases and Disorders | US15626055 | 2017-06-16 | US20170348358A1 | 2017-12-07 | Elizabeth McKenna |
| The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes. | ||||||
| 10 | Streptococcal C5a peptidase vaccine | US10915705 | 2004-08-10 | US20050136068A1 | 2005-06-23 | Paul Cleary; Deborah Stafslien |
| Novel vaccines for use against β-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against β-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed. | ||||||
| 11 | Streptococcal C5a peptidase vaccine | US09870122 | 2001-05-30 | US20020142009A1 | 2002-10-03 | Paul Patrick Cleary; Deborah K. Stafslien |
| Novel vaccines for use against null-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against null-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed. | ||||||
| 12 | アウリントリカルボン酸合成複合体の低分子量成分による、補体の膜侵襲複合体およびＣ３転換酵素の選択的阻害 | JP2015521077 | 2012-07-13 | JP2015522060A | 2015-08-03 | パトリック マクギアー、; ムンヒ イ、; ジャン−ピン グオ、; クラウディア シュワブ、 |
| アウリントリカルボン酸複合体の分子量1キロダルトン未満の成分を用いて、哺乳類種、好ましくはヒトにおける補体の膜侵襲複合体を選択的に阻害する。好ましい阻害剤はアウリントリカルボン酸、アウリンクアドラカルボン酸、およびアウリンヘキサカルボン酸である。補体の膜侵襲複合体の選択的阻害により治療されるために好ましい疾患は、加齢黄斑変性、アルツハイマー病、アテローム性動脈硬化症、関節リウマチ、発作性夜間血色素尿症、マラリア感染症、および多発性硬化症である。 | ||||||
| 13 | Streptococcal C5a peptidase vaccine | JP2000586920 | 1999-12-03 | JP2002531584A | 2002-09-24 | パトリック クリアリー，ポール; ケー． スタッフスリーン，デボラ |
| (57)【要約】 β溶血連鎖球菌属（Streptococcus）の定着および感染に対して用いられる新規ワクチンが開示される。 このワクチンは、免疫原性量の連鎖球菌Ｃ５ａペプチダーゼ（ＳＣＰ）変異体を含有する。 そのようなワクチンを投与することによりβ溶血連鎖球菌属の定着または感染に対して感受性哺乳動物を防御する方法も開示される。 更に、酵素的に不活性なＳＣＰ、およびそれらのＳＣＰタンパク質をコードするポリヌクレオチドも開示される。 | ||||||
| 14 | SELECTIVE INHIBITION OF THE MEMBRANE ATTACK COMPLEX OF COMPLEMENT AND C3 CONVERTASE BY LOW MOLECULAR WEIGHT COMPONENTS OF THE AURIN TRICARBOXYLIC ACID SYNTHETIC COMPLEX | EP12880850 | 2012-07-13 | EP2872130A4 | 2016-06-22 | MCGEER PATRICK; LEE MOONHEE; GUO JIAN-PING; SCHWAB CLAUDIA |
| Selective inhibition of the membrane attack complex of complement in a mammalian species, preferably human, with components of the aurin tricarboxylic acid complex of less than 1 kilodalton in molecular weight. Preferred inhibitors are aurin tricarboxylic acid, aurin quadracarboxylic acid and aurin hexacarboxylic acid. Preferred disease to be treated by elective inhibition of the membrane attack complex of complement are age-related macular degeneration, Alzheimer's disease, atherosclerosis, rheumatoid arthritis, paroxysmal nocturnal hemoglobinemia, malaria infection and multiple sclerosis. | ||||||
| 15 | Streptococcal C5a peptidase vaccine | EP07015995.9 | 1999-12-03 | EP1892298B1 | 2011-03-23 | Cleary, Paul Patrick; Stafslien, Deborah K. |
| 16 | METHODS AND COMPOSITIONS FOR TREATMENT OF GAUCHER DISEASE VIA MODULATION OF C5A RECEPTOR | US15758016 | 2016-08-29 | US20180243370A1 | 2018-08-30 | Manoj Kumar Pandey |
| Disclosed are compositions and methods for the reduction of C5a mediated immune inflammation. The methods, in various aspects, may include the step of administering a C5aR antagonist to a subject in need of such treatment. In one aspect, the subject in need may have a lysosomal acid storage disease. Therapeutic kits and articles of manufacture are also disclosed. | ||||||
| 17 | Control of Cellular Redox Levels | US15348005 | 2016-11-10 | US20170232047A1 | 2017-08-17 | Elizabeth McKenna |
| Disclosed herein are compositions and methods for regulating redox status and/or reducing oxidative stress in a subject, the methods and compositions comprising TLR agonists comprising bacterial lysates and/or lysate fractions. Also disclosed are compositions and methods comprising bacterial lysates and/or lysate fractions formulated or administered in combination with one or more other therapeutic or pharmaceutical agents. | ||||||
| 18 | Compositions and methods for the treatment of hepatic diseases and disorders | US13743194 | 2013-01-16 | US09713630B2 | 2017-07-25 | Elizabeth McKenna |
| The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes. | ||||||
| 19 | Heparin affinity tag and applications thereof | US14378230 | 2014-01-21 | US09676816B2 | 2017-06-13 | Suresh Kumar Thallapuranam; Srinivas Jayanthi; Jacqueline Morris; Alicia Brown; David McNabb; Ralph Henry |
| In one aspect, affinity tags for recombinant protein purification are described herein which, in some embodiments, can mitigate or overcome disadvantages of prior affinity tag systems. In some embodiments, for example, affinity tags described herein permit efficient elution of desired recombinant proteins with simplified solution systems, such as alkali metal salt solutions. An affinity tag described herein comprises an amino acid sequence including a repeating amino acid unit of BXXXBXX, wherein B is an amino acid selected from the group consisting of histidine, lysine and arginine and X is an amino acid selected from the group consisting of amino acids other than histidine, lysine and arginine. | ||||||
| 20 | HEPARIN AFFINITY TAG AND APPLICATIONS THEREOF | US14378230 | 2014-01-21 | US20160145597A1 | 2016-05-26 | Suresh Kumar Thallapuranam; Srinivas Jayanthi; Jacqueline Morris; Alicia Brown; David McNabb; Ralph Henry |
| In one aspect, affinity tags for recombinant protein purification are described herein which, in some embodiments, can mitigate or overcome disadvantages of prior affinity tag systems. In some embodiments, for example, affinity tags described herein permit efficient elution of desired recombinant proteins with simplified solution systems, such as alkali metal salt solutions. An affinity tag described herein comprises an amino acid sequence including a repeating amino acid unit of BXXXBXX, wherein B is an amino acid selected from the group consisting of histidine, lysine and arginine and X is an amino acid selected from the group consisting of amino acids other than histidine, lysine and arginine. | ||||||
QQ群二维码
意见反馈
意见反馈